Yükleniyor... / Loading...
This non-interventional study explores the attitudes, beliefs and opinions of people with sickle cell disease (SCD), parents of people with SCD, and their providers regarding the use of CRISPR Cas9 gene editing in clinical trials and treatment. As described in the study, SCD is caused by a genetic defect affecting how hemoglobin is made, and research has used CRISPR Cas9 to correct the sickle cell gene in animal models and human cells. Eligible participants include English-speaking adults aged 18 or older with an SCD diagnosis, adult parents of a child with SCD, and providers caring for these patients.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
* INCLUSION CRITERIA: The inclusion criteria for patients: 1. must have a diagnosis of sickle cell disease 2. must be 18 years or older 3. must be English-speaking The inclusion criteria for parents of patients with SCD: 1. must have a child with sickle cell disease 2. must be 18 years or older 3. must be English speaking Lastly, the inclusion criteria for physicians: 1. must care for sickle cell patients 2. must have cared for sickle cell patients for a minimum of 12 months 3. must have been the caregiver for at least five adult patients and/or five pediatric patients 4. must be 18 years or older 5. must be English-speaking. The participants need to be 18 years or older in order to provide informed consent. It is necessary that participants speak English due to the nature of the study. Because a moderated conversation will take place, it is essential that all participants and researchers speak the same language to allow for interactive discourse and comprehension.